

Module 3 - Section 2.P.8.3 - Stability Data

Stability Study Summary
Bicalutamide 150 mg film-coated tablets

Version number:	SSS.NUS.BCM.tab150.002 (10.0)
Supersedes document of issue date:	SSS.NUS.BCM.tab150.002 (9.0), electronically controlled
Number of appendices:	Two
Prepared by:	Paulien Smits
Document length:	26 pages

Contents:

1	Introduction.....	3
2	Overview long term stability data.....	4
2.1	Long term stability study: 25 °C/60 % RH blister (PVC/PE/PVDC:Al).....	4
2.2	Long term stability study: 25 °C/60 % RH Bulk packaging.....	10
3	Overview intermediate stability data.....	12
3.1	Intermediate stability study: 30 °C/65 % RH blister (PVC/PE/PVDC:Al) ...	12
3.2	Intermediate stability study: 30 °C/65 % RH Bulk packaging	18
4	Overview accelerated stability data.....	20
4.1	Accelerated stability study: 40 °C/75 % RH blister (PVC/PE/PVDC:Al)	20
5	Stability data of other batches.....	¡Error! Marcador no definido.

1 Introduction

In this Stability Study Summary, the data regarding Bicalutamide 150 mg tablets are presented. These data are gathered as a result of the execution of SDE.NUS.BCM.tab150.002.

Explanation of terms used in this Stability Study Summary:

Long term study: 25 °C / 60% RH

Intermediate study: 30 °C / 65% RH

Accelerated study: 40 °C / 75% RH

C: Complies with specification

NC: Does not comply with specification

--: Not performed or no results available

2 Overview long term stability data

2.1 Long term stability study: 25 °C/60 % RH blister (PVC/PE/PVDC:Al)

In this part of the stability study summary, the results of Bicalutamide 150 mg tablets, packaged in a PVC/PE/PVDC:Al blister and stored at 25 °C/60 % RH are presented.

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 5/26

Product / strength:	Bicalutamide 150mg			Packaged lot number:			04D21IEA						
Storage condition:	25°C/60% RH			Batch size:			50000 tablets						
Study start date:	14/05/2004			Packaging			30 tablets						
Packaging:	PVC/PE/PVDC/Alu			Closure:			NA						
Bulk batch number:	04D21IE			Drug substance:			Bicalutamide						
Bulk Mfg. Date:	21/04/2004			Drug substance Mfg:			Synthon sro						
Bulk Mfg. site:	Synthon Hispania			Drug substance lot number:			57621						
Tests	Time in months			0	3	6	9	12	18	24	36	48	60
Appearance:	C			C	C	C	C	C	C	C	C	C	C
Seal integrity of the blister/container:	C			C	C	C	C	C	C	C	C	C	C
Uniformity of dosage units	C			C	C	C	C	C	C	C	C	C	C
Dissolution:	Min	Ave	Min	Ave	Min	Ave	Min	Ave	Min	Ave	Min	Ave	Min
- in 30 minutes	77	83	82	84	81	77	83	78	83	80	85	74	83
Identification (HPLC):	C	C	C	C	C	C	C	C	C	C	C	C	C
Assay (HPLC) [mg/tab]:	146.4	144.2	147.0	147.3	151.6	147.0	147.2	146.5	143.8	145.6	144.3	144.3	144.3
- % of declared value	98	96	98	98	101	98	98	98	96	97	96	96	96
Impurities (HPLC):	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- A/509	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.06
- Largest unidentified impurity	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.06
- Total unidentified impurities	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.06
- Total impurities	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.07	0.06
Microbial contamination													
- Total viable aerobic count	C	---	---	C	---	---	---	C	---	C	C	C	C
- Aerobic bacteria:	C	---	---	C	---	---	---	C	---	C	C	C	C
- Fungi:	---	---	---	C	---	---	---	C	---	C	C	C	C
- Escherichia coli:	---	---	---	C	---	---	---	C	---	C	C	C	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 6/26

Product / strength: Storage condition: Study start date: Packaging:	Bicalutamide 150mg 25°C/60% RH 19/05/2004 PVC/PE/PVDC/Al	Packaged lot number: Batch size: Packaging Closure:		04D261EA 50000 tablets 30 tablets NA							
Bulk batch number: Bulk Mfg. Date: Bulk Mfg.site:	04D261E 26/04/2004 Synthon Hispania	Drug substance: Drug substance Mfg: Drug substance lot number:		Bicalutamide Synthon sro 57630							
Tests	Time in months	0	3	6	9	12	18	24	36	48	60
Appearance:		C	C	C	C	C	C	C	C	C	C
Seal integrity of the blister/container:		C	C	C	C	C	C	C	C	C	C
Uniformity of dosage units		C	C	C	C	C	C	C	C	C	C
Dissolution:		Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave
- in 30 minutes		80 85	86 89	77 83	83 86	64 78	76 80	74 81	82 85	81 85	75 78
Identification (HPLC):		C	C	C	C	C	C	C	C	C	C
Assay (HPLC) [mg/tab]:		146.0	145.7	147.2	152.2	147.6	150.1	144.1	146.1	148.2	143.1
- % of declared value		97	97	98	101	98	100	96	97	99	95
Impurities (HPLC):		≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- A/509		0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.07
- Largest unidentified impurity		0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.07
- Total unidentified impurities		0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.07
- Total impurities		0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.07
Microbial contamination											
- Total viable aerobic count		C	---	C	---	C	---	C	C	C	C
- Aerobic bacteria:		C	---	C	---	C	---	C	C	C	C
- Fungi:		---	---	C	---	C	---	C	C	C	C
- Escherichia coli:		---	---	C	---	C	---	C	C	C	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 7/26

Product / strength: Storage condition: Study start date:	Bicalutamide 150mg 25°C/60% RH 19/05/2004		Packaged lot number: Batch size: Packaging		04D28IEA 50000 tablets 30 tablets					
Packaging:	PVC/PE/PVDC/Al		Closure:		NA					
Bulk batch number:	04D28IE		Drug substance:		Bicalutamide					
Bulk Mfg. Date:	28/04/2004		Drug substance Mfg:		Synthon sro					
Bulk Mfg.s,ite:	Synthon Hispania		Drug substance lot number:		57621 - 57630					
Tests	0	3	6	9	12	18	24	36	48	60
Appearance:	C	C	C	C	C	C	C	C	C	C
Seal integrity of the blister/container:	C	C	C	C	C	C	C	C	C	C
Uniformity of dosage units	C	C	C	C	C	C	C	C	C	C
Dissolution:	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave
- in 30 minutes	73 80	74 81	75 79	85 85	68 75	77 81	73 79	80 83	71 82	81 82
Identification (HPLC):	C	C	C	C	C	C	C	C	C	C
Assay (HPLC) [mg/tab]:	148.8	147.2	147.6	151.3	147.2	149.0	146.5	148.5	150.0	145.8
- % of declared value	99	98	98	101	98	99	98	99	100	97
Impurities (HPLC):	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- A/509	0.07	0.06	0.07	0.06	0.06	0.07	0.06	0.08	0.06	0.06
- Largest unidentified impurity	0.07	0.06	0.07	0.06	0.06	0.07	0.06	0.08	0.06	0.06
- Total unidentified impurities	0.07	0.06	0.07	0.06	0.06	0.07	0.06	0.08	0.06	0.06
- Total impurities	0.07	0.06	0.07	0.06	0.06	0.07	0.06	0.08	0.06	0.06
Microbial contamination										
- Total viable aerobic count	C	---	C	---	C	---	C	C	C	C
- Aerobic bacteria:	C	---	C	---	C	---	C	C	C	C
- Fungi:	---	---	C	---	C	---	C	C	C	C
Escherichia coli:	---	---	C	---	C	---	C	C	C	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 8/26

Product / strength: Storage condition: Study start date:	Bicalutamide 150mg 25°C/60% RH 22/07/2005	Packaged lot number: Batch size: Packaging		05D29IEA 50000 tablets 30 tablets							
Packaging:	PVC/PE/PVDC/Alu	Closure:		NA							
Bulk batch number: Bulk Mfg. Date: Bulk Mfg. site:	05D29IE 29/04/2005 Synthon Hispania	Drug substance: Drug substance Mfg: Drug substance lot number:		Bicalutamide CF Pharma Ltd 85201							
Tests	Time in months	0	3	6	9	12	18	24	36	48	60
Appearance:	C	C	C	C	C	C	C	C	C	C	C
Seal integrity of the blister/container:	C	C	C	C	C	C	C	C	C	C	C
Uniformity of dosage units	C	C	C	C	C	C	C	C	C	C	C
Dissolution:	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave
- in 30 minutes	86 89	88 93	88 90	86 90	86 90	95 98	90 94	82 89	88 92	84 88	87 89
Identification (HPLC):	C	C	C	C	C	C	C	C	C	C	C
Assay (HPLC) [mg/tab]:	148.2	150.3	147.7	149.3	148.0	148.0	146.9	148.2	147.9	149.7	146.3
- % of declared value	99	100	98	100	99	99	98	99	99	100	98
Impurities (HPLC):											
- A/509	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Largest unidentified impurity	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total unidentified impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
Microbial contamination											
- Total viable aerobic count	C	---	C	---	C	C	---	C	C	C	C
- Aerobic bacteria:	C	---	C	---	C	C	---	C	C	C	C
- Fungi:	C	---	C	---	C	C	---	C	C	C	C
- Escherichia coli:	C	---	C	---	C	C	---	C	C	C	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 9/26

Product / strength: Storage condition: Study start date:	Bicalutamide 150mg 25°C/60% RH 22/07/2005	Packaged lot number: Batch size: Packaging Closure:				05E03 IEA 50000 tablets 30 tablets NA					
Packaging:	PVC/PE/PVDC/Al	Drug substance: Drug substance Mfg: Drug substance lot number:				Bicalutamide CF Pharma Ltd. 85198					
Bulk batch number: Bulk Mfg. Date: Bulk Mfg. site:	05E03 IE 03/05/2005 Synthon Hispania										
Tests	Time in months	0	3	6	9	12	18	24	36	48	60
Appearance:	C	C	C	C	C	C	C	C	C	C	C
Seal integrity of the blister/container:	C	C	C	C	C	C	C	C	C	C	C
Uniformity of dosage units	C	C	C	C	C	C	C	C	C	C	C
Dissolution:	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave
- in 30 minutes	90 93	92 94	90 96	89 91	90 97	92 97	84 90	85 93	87 88	96 98	
Identification (HPLC):	C	C	C	C	C	C	C	C	C	C	C
Assay (HPLC) [mg/tab]:	148.1	147.0	147.4	147.8	146.6	147.3	147.5	146.7	149.0	147.9	
- % of declared value	99	98	98	99	98	98	98	98	99	99	
Impurities (HPLC):											
- A/509	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Largest unidentified impurity	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total unidentified impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
Microbial contamination											
- Total viable aerobic count	C	---	C	---	C	---	C	C	C	C	C
- Aerobic bacteria:	C	---	C	---	C	---	C	C	C	C	C
- Fungi:	C	---	C	---	C	---	C	C	C	C	C
- Escherichia coli:	C	---	C	---	C	---	C	C	C	C	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

2.2 Long term stability study: 25 °C/60 % RH Bulk packaging

In this part of the stability study summary the results of Bicalutamide 150 mg tablets, packaged in bulk container, stored at 25 °C/60 % RH are presented.

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 11/26

Product / strength:	Bicalutamide 150mg				Packaged lot number:				04D21IE
Storage condition:	25°C/60% RH				Batch size:				50000 tablets
Study start date:	14/05/2004				Packaging				NA
Packaging:	Bulk				Closure:				NA
Bulk batch number:	04D21IE				Drug substance:				Bicalutamide
Bulk Mfg. Date:	21/04/2004				Drug substance Mfg:				Synthon sro
Bulk Mfg.site:	Synthon Hispania				Drug substance lot number:				57621
Tests	Time in months								
Appearance:	C				C				C
Uniformity of dosage units	C				C				C
Dissolution:									
- in 30 minutes	Min	Ave	Min	Ave	Min	Ave	Min	Ave	
Identification (HPLC):	77	83	79	83	82	85	78	81	84
Assay (HPLC) [mg/tab]:	C				C				C
- % of declared value	146.4		148.2		146.0		144.2		144.5
Impurities (HPLC):	98		99		97		96		96
- A/509	≤ 0.05		≤ 0.05		≤ 0.05		≤ 0.05		≤ 0.05
- Largest unidentified impurity	0.07		0.06		0.07		0.07		0.07
- Total unidentified impurities	0.07		0.06		0.07		0.07		0.07
- Total impurities	0.07		0.06		0.07		0.07		0.07
Microbial contamination									
- Total viable aerobic count	C				C				C
- Aerobic bacteria:	C				C				C
- Fungi:	---				C				C
- Escherichia coli:					C				C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

3 Overview intermediate stability data

3.1 Intermediate stability study: 30 °C/65 % RH blister (PVC/PE/PVDC:Al)

In this part of the stability study summary, the results of Bicalutamide 150 mg tablets, packaged in a PVC/PE/PVDC:Al blister, stored at 30 °C/65 % RH are presented.

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 13/26

Product / strength: Storage condition: Study start date:	Bicalutamide 150mg 30°C/65% RH 14/05/2004	Packaged lot number: Batch size: Packaging				04D21IEA 50000 tablets 30 tablets				
Packaging:	PVC/PE/PVDC/Alu	Closure:				NA				
Bulk batch number:	04D21IE	Drug substance:				Bicalutamide				
Bulk Mfg. Date:	21/04/2004	Drug substance Mfg:				Synthon sro				
Bulk Mfg. site:	Synthon Hispania	Drug substance lot number:				57621				
Tests	Time in months	0	3	6	9	12	18	24	36	48
Appearance:		C	C	C	C	C	C	C	C	C
Seal integrity of the blister/container:		C	C	C	C	C	C	C	C	C
Uniformity of dosage units		C	C	C	C	C	C	C	C	C
Dissolution:		Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave
- in 30 minutes		77 83	78 82	80 83	78 85	81 85	85 87	80 85	83 86	81 85
Identification (HPLC);		C	C	C	C	C	C	C	C	C
Assay (HPLC) [mg/tab]:		146.4	144.8	150.2	149.0	147.9	147.9	146.6	142.9	145.7
- % of declared value		98	97	100	99	99	99	98	95	97
Impurities (HPLC):										
- A/509		≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Largest unidentified impurity		0.07	0.07	0.06	0.07	0.07	0.07	0.07	0.07	≤ 0.05
- Total unidentified impurities		0.07	0.07	0.06	0.07	0.07	0.07	0.07	0.07	0.07
- Total impurities		0.07	0.07	0.06	0.07	0.07	0.07	0.07	0.07	0.07
Microbial contamination										
- Total viable aerobic count		C	---	C	---	C	---	C	C	C
- Aerobic bacteria:		C	---	C	---	C	---	C	C	C
- Fungi:		---	---	C	---	C	---	C	C	C
- Escherichia coli:		---	---	C	---	C	---	C	C	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 14/26

Product / strength: Storage condition: Study start date:	Bicalutamide 150mg 30°C/65% RH 19/05/2004	Packaged lot number: Batch size: Packaging			04D26IEA 50000 tablets 30 tablets					
Packaging:	PVC/PE/PVDC/Al	Closure:			NA					
Bulk batch number:	04D26IE	Drug substance:			Bicalutamide					
Bulk Mfg. Date:	26/04/2004	Drug substance Mfg:			Synthon sro					
Bulk Mfg.site:	Synthon Hispania	Drug substance lot number:			57630					
Tests	Time in months	0	3	6	9	12	18	24	36	48
Appearance:		C	C	C	C	C	C	C	C	C
Seal integrity of the blister/container:		C	C	C	C	C	C	C	C	C
Uniformity of dosage units		C	C	C	C	C	C	C	C	C
Dissolution:		Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave
- in 30 minutes		80 85	83 88	72 80	83 86	70 78	81 84	67 81	80 83	78 85
Identification (HPLC):		C	C	C	C	C	C	C	C	C
Assay (HPLC) [mg/tab]:		146.0	143.7	147.8	149.0	148.5	147.3	147.2	147.4	147.5
- % of declared value		97	96	99	99	99	98	98	98	98
Impurities (HPLC):										
- A/509		≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Largest unidentified impurity		0.08	0.07	0.08	0.07	0.08	0.08	0.08	0.08	0.07
- Total unidentified impurities		0.08	0.07	0.08	0.07	0.08	0.08	0.08	0.08	0.07
- Total impurities		0.08	0.07	0.08	0.07	0.08	0.08	0.08	0.08	0.07
Microbial contamination										
- Total viable aerobic count		C	---	C	---	C	---	C	C	C
- Aerobic bacteria:		C	---	C	---	C	---	C	C	C
- Fungi:		---	---	C	---	C	---	C	C	C
Escherichia coli:		---	---	C	---	C	---	C	C	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 15/26

Product / strength:	Bicalutamide 150mg	Packaged lot number:					04D28IEA				
Storage condition:	30°C/65% RH	Batch size:					50000 tablets				
Study start date:	19/05/2004	Packaging					30 tablets				
Packaging:	PVC/PE/PVDC/Al	Closure:					NA				
Bulk batch number:	04D28IE	Drug substance:					Bicalutamide				
Bulk Mfg. Date:	28/04/2004	Drug substance Mfg:					Synthon sro				
Bulk Mfg.site:	Synthon Hispania	Drug substance lot number:					57621 - 57630				
Tests	Time in months	0	3	6	9	12	18	24	36	48	
Appearance:		C	C	C	C	C	C	C	C	C	
Seal integrity of the blister/container:		C	C	C	C	C	C	C	C	C	
Uniformity of dosage units		C	C	C	C	C	C	C	C	C	
Dissolution:		Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	
- in 30 minutes		73 80	80 82	65 75	80 85	68 76	81 83	72 81	83 85	74 83	
Identification (HPLC):		C	C	C	C	C	C	C	C	C	
Assay (HPLC) [mg/tab]:		148.8	150.5	147.8	151.5	147.6	151.6	147.1	145.8	151.0	
- % of declared value		99	100	99	101	98	101	98	97	101	
Impurities (HPLC):		≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	
- A/509		0.07	0.06	0.07	0.06	0.07	0.07	0.06	0.07	0.06	
- Largest unidentified impurity		0.07	0.06	0.07	0.06	0.07	0.07	0.06	0.07	0.06	
- Total unidentified impurities		0.07	0.06	0.07	0.06	0.07	0.07	0.06	0.07	0.06	
- Total impurities		0.07	0.06	0.07	0.06	0.07	0.07	0.06	0.07	0.06	
Microbial contamination											
- Total viable aerobic count		C	---	C	---	C	---	C	C	C	
- Aerobic bacteria:		C	---	C	---	C	---	C	C	C	
- Fungi:		---	---	C	---	C	---	C	C	C	
- Escherichia coli:		---	---	C	---	C	---	C	C	C	

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 16/26

Product / strength: Storage condition: Study start date:	Bicalutamide 150mg 30°C/65% RH 22/07/2005	Packaged lot number: Batch size: Packaging	05D29IEA 50000 tablets 30 tablets						
Packaging:	PVC/PE/PVDC/Alu	Closure:	NA						
Bulk batch number:	05D29IE	Drug substance:	Bicalutamide						
Bulk Mfg. Date:	29/04/2005	Drug substance Mfg:	CF Pharma Ltd						
Bulk Mfg.site:	Synthon Hispania	Drug substance lot number:	85201						
Tests	Time in months	0	3	6	9	12	18	24	36
Appearance:	C	C	C	C	C	C	C	C	C
Seal integrity of the blister/container:	C	C	C	C	C	C	C	C	C
Uniformity of dosage units	C	C	C	C	C	C	C	C	C
Dissolution:	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave	Min Ave
- in 30 minutes	86 89	87 90	90 91	80 86	90 96	88 95	84 88	89 93	89 93
Identification (HPLC);	C	C	C	C	C	C	C	C	C
Assay (HPLC) [mg/tab]:	148.2	150.5	148.8	150.5	145.4	150.1	150.7	151.4	151.4
- % of declared value	99	100	99	100	97	100	100	101	101
Impurities (HPLC):	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- A/509	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Largest unidentified impurity	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total unidentified impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
Microbial contamination									
- Total viable aerobic count	C	---	C	---	C	---	C	C	C
- Aerobic bacteria:	C	---	C	---	C	---	C	C	C
- Fungi:	C	---	C	---	C	---	C	C	C
- Escherichia coli:	C	---	C	---	C	---	C	C	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 17/26

Product / strength:	Bicalutamide 150mg			Packaged lot number:			05E03IEA		
Storage condition:	30°C/65% RH			Batch size:			50000 tablets		
Study start date:	22/07/2005			Packaging			30 tablets		
Packaging:	PVC/PE/PVDC/Al			Closure:			NA		
Bulk batch number:	05E03IE			Drug substance:			Bicalutamide		
Bulk Mfg. Date:	03/05/2005			Drug substance Mfg:			CF Pharma Ltd.		
Bulk Mfg. site:	Synthon Hispania			Drug substance lot number:			85198		
Tests	Time in months								
Appearance:	C			C			C		
Seal integrity of the blister/container:	C			C			C		
Uniformity of dosage units	C			C			C		
Dissolution:									
- in 30 minutes	Min	Ave	Min	Ave	Min	Ave	Min	Ave	Min
Identification (HPLC):	90	93	90	93	90	93	90	93	90
Assay (HPLC) [mg/tab]:	148.1	149.1	149.4	148.8	148.5	149.7	148.5	149.5	149.5
- % of declared value	99	99	100	99	99	100	99	100	100
Impurities (HPLC):									
- A/509	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Largest unidentified impurity	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total unidentified impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
Microbial contamination									
- Total viable aerobic count									
¹ - Aerobic bacteria:	C	---	C	---	C	---	C	---	C
¹ - Fungi:	C	---	C	---	C	---	C	---	C
- Escherichia coli:	C	---	C	---	C	---	C	---	C

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

3.2 Intermediate stability study: 30 °C/65 % RH Bulk packaging

In this part of the stability study summary, the results of Bicalutamide 150 mg tablets, packaged in a bulk container stored at 30 °C/65 % RH are presented.

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 19/26

Product / strength:	Bicalutamide 150mg				Packaged lot number:				04D21IE			
Storage condition:	30°C/65% RH				Batch size:				50000 tablets			
Study start date:	14/05/2004				Packaging				NA			
Packaging:	Bulk				Closure:				NA			
Bulk batch number:	04D21IE				Drug substance:				Bicalutamide			
Bulk Mfg. Date:	21/04/2004				Drug substance Mfg:				Synthon sro			
Bulk Mfg.site:	Synthon Hispania				Drug substance lot number:				57621			
Tests	Time in months											
Appearance:	0				6				12			
Uniformity of dosage units	C				C				C			
Dissolution:	C				C				C			
- in 30 minutes	Min Ave				Min Ave				Min Ave			
Identification (HPLC):	77 83				80 85				82 85			
Assay (HPLC) [mg/tab]:	146.4				147.4				146.7			
- % of declared value	98				98				98			
Impurities (HPLC):	≤ 0.05				≤ 0.05				≤ 0.05			
- A/509	0.07				0.07				0.07			
- Largest unidentified impurity	0.07				0.07				0.07			
- Total unidentified impurities	0.07				0.07				0.07			
- Total impurities	0.07				0.07				0.07			
Microbial contamination												
- Total viable aerobic count	C				C				C			
- Aerobic bacteria:	C				C				C			
- Fungi:	---				C				C			
- Escherichia coli:					C				C			

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

4 Overview accelerated stability data

4.1 Accelerated stability study: 40 °C/75 % RH blister (PVC/PE/PVDC:Al)

In this part of the stability study summary, the results of Bicalutamide 150 mg tablets, packaged in a PVC/PE/PVDC:Al blister, stored at 40 °C/75 % RH are presented.

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 21/26

Product / strength:	Bicalutamide 150mg				Packaged lot number:				04D21IEA			
Storage condition:	40°C/75% RH				Batch size:				50000 tablets			
Study start date:	14/05/2004				Packaging				30 tablets			
Packaging:	PVC/PE/PVDC/Alu				Closure:				NA			
Bulk batch number:	04D21IE				Drug substance:				Bicalutamide			
Bulk Mfg. Date:	21/04/2004				Drug substance Mfg:				Synthon sro			
Bulk Mfg.site:	Synthon Hispania				Drug substance lot number:				57621			
Tests	Time in months											
Appearance:	0				1				2			
Seal integrity of the blister/container:	C				C				C			
Uniformity of dosage units	C				C				C			
Dissolution:	C				C				C			
- in 30 minutes	Min Ave				Min Ave				Min Ave			
Identification (HPLC):	77 83 80 85				82 85 86 81				84 81 84			
Assay (HPLC) [mg/tab]:	146.4				147.6				143.6			
- % of declared value	98				98				96			
Impurities (HPLC):	≤ 0.05				≤ 0.05				≤ 0.05			
- A/509	0.07				0.07				0.06			
- Largest unidentified impurity	0.07				0.07				0.07			
- Total unidentified impurities	0.07				0.07				0.06			
- Total impurities	0.07				0.07				0.06			

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Hewlett-Packard
Company

Module 3 - Section 2.P.8.3 - Stability Data

page 22/26

Product / strength:	Bicalutamide 150mg				Packaged lot number:				04D261EA			
Storage condition:	40°C/75% RH				Batch size:				50000 tablets			
Study start date:	19/05/2004				Packaging				30 tablets			
Packaging:	PVC/PE/PVDC/Al				Closure:				NA			
Bulk batch number:	04D261E				Drug substance:				Bicalutamide			
Bulk Mfg. Date:	26/04/2004				Drug substance Mfg:				Synthon sro			
Bulk Mfg.site:	Synthon Hispania				Drug substance lot number:				57621 - 57630			
Tests	0	1	2	3	6	12						
Appearance:	C	C	C	C	C(*)	C						
Seal integrity of the blister/container:	C	C	C	C	C	C						
Uniformity of dosage units	C	C	C	C	C	C						
Dissolution:	Min	Ave	Min	Ave	Min	Ave	Min	Ave	Min	Ave		
- in 30 minutes	80	85	82	85	82	85	82	87	82	84	75	
Identification (HPLC):	C	C	C	C	C	C	C	C	C	C		
Assay (HPLC) [mg/tab]:	146.0	145.8	147.1	145.7	145.5	149.3						
- % of declared value	97	97	98	97	97	100						
Impurities (HPLC):												
- A/509	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05						
- Largest unidentified impurity	0.08	0.08	0.08	0.08	0.09	0.08						
- Total unidentified impurities	0.08	0.08	0.08	0.08	0.09	0.08						
Total impurities	0.08	0.08	0.08	0.08	0.09	0.08						

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Module 3 - Section 2.P.8.3 - Stability Data

page 23/26

Product / strength:	Bicalutamide 150mg				Packaged lot number:				04D281EA			
Storage condition:	40°C/75% RH				Batch size:				50000 tablets			
Study start date:	19/05/2004				Packaging				60 tablets			
Packaging:	PVC/PE/PVDC/Al				Closure:				NA			
Bulk batch number:	04D281E				Drug substance:				Bicalutamide			
Bulk Mfg. Date:	28/04/2004				Drug substance Mfg:				Synthon s ro			
Bulk Mfg.site:	Synthon Hispania				Drug substance lot number:				57630			
Tests	Time in months											
Appearance:	0				1				2			
Seal integrity of the blister/container:	C				C				C			
Uniformity of dosage units	C				C				C			
Dissolution:	C				C				C			
- in 30 minutes	Min Ave				Min Ave				Min Ave			
Identification (HPLC);	73 80 80 84				75 82 75 80				78 82 75 80			
Assay (HPLC) [mg/tab];	148.8				149.0				146.1			
- % of declared value	99				99				97			
Impurities (HPLC):	≤ 0.05				≤ 0.05				≤ 0.05			
- A/509	≤ 0.05				≤ 0.05				≤ 0.05			
- Largest unidentified impurity	0.07				0.07				0.06			
- Total unidentified impurities	0.07				0.07				0.13			
- Total impurities	0.07				0.07				0.13			

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Module 3 - Section 2.P.8.3 - Stability Data

page 24/26

Product / strength:	Bicalutamide 150mg				Packaged lot number:				05D29IEA	
Storage condition:	40°C/75% RH				Batch size:				50000 tablets	
Study start date:	22/07/2005				Packaging				30 tablets	
Packaging:	PVC/PE/PVDC/Alu				Closure:				NA	
Bulk batch number:	05D29IE				Drug substance:				Bicalutamide	
Bulk Mfg. Date:	29/04/2005				Drug substance Mfg:				CF Pharma Ltd	
Bulk Mfg.site:	Synthon Hispania				Drug substance lot number:				85201	
Tests	Time in months				0	1	2	3	6	12
Appearance:	C				C				C	
Seal integrity of the blister/container:	C				C				C	
Uniformity of dosage units	C				C				C	
Dissolution:										
- in 30 minutes	Min	Ave	Min	Ave	Min	Ave	Min	Ave	Min	Ave
Identification (HPLC):	86	89	86	89	86	89	88	90	87	94
Assay (HPLC) [mg/tab]:	C				C				C	
- % of declared value	148.2		148.8		149.8	148.8	149.8	148.8	149.9	148.4
Impurities (HPLC):	99		99		100	99	100	99	100	99
- A/509	≤ 0.05		≤ 0.05		≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Largest unidentified impurity	≤ 0.05		≤ 0.05		≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total unidentified impurities	≤ 0.05		≤ 0.05		≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
Total impurities	≤ 0.05		≤ 0.05		≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

Stability Study Summary
Bicalutamide 150 mg
film-coated tablets

Module 3 - Section 2.P.8.3 - Stability Data

page 25/26

Product / strength: Storage condition: Study start date:	Bicalutamide 150mg 40°C/75% RH 22/07/2005		Packaged lot number: Batch size: Packaging		05E03 IEA 50000 tablets 30 tablets			
Packaging:	PVC/PE/PVDC/Al		Closure:		NA			
Bulk batch number:	05E03 IE		Drug substance:		Bicalutamide			
Bulk Mfg. Date:	03/05/2005		Drug substance Mfg:		CF Pharma Ltd.			
Bulk Mfg.site:	Synthon Hispania		Drug substance lot number:		85198			
Tests	Time in months		0	1	2	3	6	12
Appearance:	C		C	C	C	C	C	C
Seal integrity of the blister/container:	C		C	C	C	C	C	C
Uniformity of dosage units	C		C	C	C	C	C	C
Dissolution:								
- in 30 minutes	Min	Ave	Min	Ave	Min	Ave	Min	Ave
Identification (HPLC):	90	93	86	90	89	92	95	93
Assay (HPLC) [mg/tab]:	148.1	147.8	148.2	148.2	148.2	147.5	150.6	148.7
- % of declared value	99	99	99	99	99	98	100	99
Impurities (HPLC):								
- A/509	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Largest unidentified impurity	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
- Total unidentified impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05
Total impurities	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05	≤ 0.05

electronically controlled

version: SSS.NUS.BCM.tab150.002 (10.0)

